These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33209890)

  • 1. Pretreatment systemic inflammation response index (SIRI) is an independent predictor of survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy: a two-center retrospective study.
    Hu M; Xu Q; Yang S; Han S; Zhu Y; Lin Q; Sun X; Liu H; Xu Y
    Ann Transl Med; 2020 Oct; 8(20):1310. PubMed ID: 33209890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy.
    Yang H; Wang K; Li B; Li S; Li Y; Yuan L
    Front Oncol; 2021; 11():707041. PubMed ID: 34917497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.
    Kucuk A; Ozkan EE; Eskici Oztep S; Mertsoylu H; Pehlivan B; Selek U; Topkan E
    J Oncol; 2020; 2020():8832145. PubMed ID: 33381177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.
    Chen L; Chen Y; Zhang L; Xue Y; Zhang S; Li X; Song H
    Pathol Oncol Res; 2021; 27():1609811. PubMed ID: 34712105
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictive effect of the systemic inflammation response index (SIRI) on the efficacy and prognosis of neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
    Ding Y; Liu Z; Li J; Niu W; Li C; Yu B
    BMC Surg; 2024 Mar; 24(1):89. PubMed ID: 38481180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of systemic inflammation response index in hepatoblastoma patients receiving preoperative neoadjuvant chemotherapy.
    Zheng C; Ye S; Liu W; Diao M; Li L
    Front Oncol; 2023; 13():1276175. PubMed ID: 37901310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
    Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
    [No Abstract]   [Full Text] [Related]  

  • 8. The Pretreatment Systemic Inflammation Response Index as a Useful Prognostic Factor is Better Than Lymphocyte to Monocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
    Jiang C; Zhang S; Qiao K; Xiu Y; Yu X; Huang Y
    Clin Breast Cancer; 2022 Jul; 22(5):424-438. PubMed ID: 35428593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining the systemic inflammation response index and prognostic nutritional index to predict the prognosis of locally advanced elderly esophageal squamous cell carcinoma patients undergoing definitive radiotherapy.
    Yan K; Wei W; Shen W; Du X; Zhu S; Zhao H; Wang X; Yang J; Zhang X; Deng W
    J Gastrointest Oncol; 2022 Feb; 13(1):13-25. PubMed ID: 35284132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis.
    Topkan E; Selek U; Kucuk A; Haksoyler V; Ozdemir Y; Sezen D; Mertsoylu H; Besen AA; Bolukbasi Y; Ozyilkan O; Pehlivan B
    J Oncol; 2021; 2021():6688138. PubMed ID: 33552158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator.
    Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
    Cancer Manag Res; 2020; 12():1543-1567. PubMed ID: 32184659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy.
    Topkan E; Mertsoylu H; Kucuk A; Besen AA; Sezer A; Sezen D; Bolukbasi Y; Selek U; Pehlivan B
    Gastroenterol Res Pract; 2020; 2020():5701949. PubMed ID: 32802045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of systemic inflammatory and nutritional indexes in locally advanced gastric cancer treated with adjuvant chemoradiotherapy after D2 dissection.
    Wang SB; Chen JY; Xu C; Cao WG; Cai R; Cao L; Cai G
    Front Oncol; 2022; 12():1040495. PubMed ID: 36387250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
    Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
    Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative systemic inflammation response index indicates poor prognosis in patients treated with resection of renal cell carcinoma with inferior vena cava tumor thrombus.
    Lv Z; Feng HY; Wang T; Ma X; Zhang X
    Urol Oncol; 2022 Apr; 40(4):167.e9-167.e19. PubMed ID: 35042663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of the Systemic Inflammation Response Index in Patients with Adenocarcinoma of the Oesophagogastric Junction: A Propensity Score-Matched Analysis.
    Chen Y; Jin M; Shao Y; Xu G
    Dis Markers; 2019; 2019():4659048. PubMed ID: 31781301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Inflammation Response Index Predicts Survival Outcomes in Glioblastoma Multiforme Patients Treated with Standard Stupp Protocol.
    Topkan E; Kucuk A; Ozdemir Y; Mertsoylu H; Besen AA; Sezen D; Bolukbasi Y; Pehlivan B; Selek U
    J Immunol Res; 2020; 2020():8628540. PubMed ID: 33274245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.